Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapies

Leukemia & Lymphoma
C Rosenfeld, H Kantarjian

Abstract

Acute myelogenous leukemia (AML) can be separated by whether the presentation was proceeded by a myelodysplastic (MDS related AML) or developed de novo (dAML). Clinically, MDS related AML (mAML) has been considered to have a worse prognosis that dAML. The objective of this literature review was to identify unique biologic features of mAML. Compared to dAML, mAML is characterized by an altered immunophenotype (increased frequency of CD34, CD11b and CD25), lack of leukemic progenitor cell suppression due to TGFbeta1, increased bcl-2 expression, presence of inducible nitric oxide synthase, lower levels or mrp transcripts and increased expression of p53. Possible interpretations of these differences between mAML and dAML are presented. Implications for mAML directed therapy are discussed.

Associated Clinical Trials

Nov 11, 2008·Marc Gautier, Marc Gautier

References

Feb 1, 1992·American Journal of Hematology·S A SullivanM E Jones
May 1, 1990·American Journal of Hematology·D GuyotatD Fiere
Mar 1, 1995·The Journal of Clinical Investigation·O YamadaH Mizoguchi
Jul 1, 1993·European Journal of Haematology·M KitagawaT Kasuga
Feb 1, 1996·British Journal of Haematology·A OrianiG Lambertenghi Deliliers
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R BishopA Kessinger
May 1, 1996·Bulletin of Environmental Contamination and Toxicology·J C KisselR A Fenske
Sep 1, 1996·Current Microbiology·P Ramirez-SalgadoF Gutierrez-Corona
Mar 1, 1996·Baillière's Clinical Haematology·G E de Greef, A Hagemeijer
Dec 12, 1997·American Journal of Hematology·J BoultwoodJ S Wainscoat
Sep 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D G Kirsch, M B Kastan
May 27, 1999·Seminars in Cancer Biology·T Veikkola, K Alitalo
Jul 20, 1999·The Journal of Clinical Investigation·A AshkenaziR H Schwall
Sep 1, 1999·British Journal of Haematology·J F Dimartino, M L Cleary
Sep 4, 1999·Leukemia Research·Y Yoshida, G J Mufti
Dec 22, 1999·British Journal of Cancer·G PruneriF Pezzella
Dec 28, 1999·Leukemia & Lymphoma·B Quesnel, P Fenaux
Mar 4, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·N L HarrisC D Bloomfield
May 4, 2000·The New England Journal of Medicine·G C BlobeH F Lodish

❮ Previous
Next ❯

Citations

Apr 3, 2004·British Journal of Haematology·Francesco BuccisanoValter Gattei
Jun 13, 2002·Reviews in Clinical and Experimental Hematology·Theo de WitteAnton Schattenberg
Mar 22, 2006·American Journal of Hematology·Michaela GrafHelga Schmetzer
Mar 21, 2007·Journal of the American Podiatric Medical Association·Michael A Schreck

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.